CTF Europe Launch Event

On November 7, 2018, the Children's Tumor Foundation Europe hosted a special event in Brussels, Belgium to celebrate the formation of the organization in its special mission to help end NF in Europe and beyond. Held at the beautiful Musical Instrument Museum, the celebration was attended by patients, researchers, pharma execs, European Union representatives and many others. Click below to read more about this inaugural event.

Watch the keynote speech of Magda Chlebus, Executive Director, Science Policy & Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA).

Watch the introductory video explaining what the launch of CTF Europe will mean for NF patients all over the world.

Founded in 1978, CTF (HQ in New York City) is the largest nongovernmental funder and catalyzer of neurofibromatosis (NF) research in the world, with its mission to drive research, expand knowledge, and advance care for the NF community. NF affects 1 in 3,000 births and impacts all populations, genders, and ethnicities equally, meaning that NF affects about 250,000 Europeans, or over 2.5 million people worldwide. NF causes tumors to grow on nerves throughout the body and can lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer.

Over the past 40 years, CTF has always funded the best and brightest research no matter where the research is carried out. Many European laboratories and clinicians have benefited from CTF funding over time. As a research catalyzer, CTF organizes the largest international NF meeting in the world. And, in the 40th anniversary year, CTF partnered with European NF groups to organize the first global NF conference in Paris.

There is no cure yet – but Children’s Tumor Foundation research is making great progress, including encouraging clinical trial results for selumetinib, which recently received orphan drug status from both the European Medicines Agency and the U.S. Food and Drug Administration, and likely will be the first ever approved drug for NF. The Children’s Tumor Foundation is also the NF package lead for the new European Innovative Medicines Initiative (IMI) call focused on patient-centric drug development. The focus of Children’s Tumor Foundation Europe will be to further build out relationships with the European agencies while maintaining its commitment to funding and driving innovative research worldwide that will result in effective treatments for NF.

We envision a day when NF patients can live their lives free of the pain and difficulties that come with NF, and that day is on the horizon because of CTF’s innovative team-based approach to drug development. By bringing together the best and brightest minds in Europe, the United States, and around the world, we will advance cures not just for NF but other rare diseases as well. Join us as we revolutionize how treatments are developed for those who need them most.

NF knows no bounderies, and neither does the fight to end NF. Joins us as we launch this new phase in NF research across the globe.

For more information, contact Children's Tumor Foundation Europe at:
Belgium +32466901234 or United States 1-212-344-6633